

A cohort study of COVID-19 infection in pediatric oncology patients and the utility of remdesivir treatment

Rina Yue Ling Ong¹, Valerie Xue Fen Seah¹, Chia-Yin Chong¹, Koh Cheng Thoon¹, Natalie Woon Hui Tan¹, Jiahui Li¹, Karen Donceras Nadua¹, Shui Yen Soh¹, Michaela Su-Fern Seng¹, Thi Ngoc Anh Pham¹, Chee Fu Yung¹, and Kai-Qian Kam¹

¹KK Women's and Children's Hospital

October 28, 2022

Abstract

Introduction Pediatric oncology patients are reportedly at risk for progression to severe Coronavirus disease-2019 (COVID-19) infection. Data on the safety and clinical effectiveness of remdesivir in children with cancer remains scarce. The main aims of this study were to describe COVID-19 infection in this cohort and to evaluate the utility of remdesivir treatment in terms of the time to viral clearance and its safety profile. **Methods** This was a retrospective observational cohort study of pediatric oncology patients [?]18 years of age with SARS-CoV-2 polymerase chain reaction (PCR) confirmed infection. Patients were admitted to KK Women's and Children's Hospital from 1st November 2021 to 31st March 2022. Clinical data, investigations and laboratory tests results were collected. **Results** Eighteen patients were included. Median age was 6.5 years (IQR: 4.64 – 9.83), and there were 13 males (72.2%). The immunosuppressive status of the cohort was: severe (n = 3, 22.2%), moderate (n = 9, 50.0%) and low (5, 27.8%). All patients had mild COVID-19 infection, and there were no COVID-19 attributed deaths. Remdesivir was initiated in four patients. We did not detect any benefit in terms of time to viral clearance or SARS-CoV2 PCR cycle threshold [?]25 between the treated versus non-treated groups. Remdesivir was well tolerated with no safety concerns. **Conclusion** Our cohort of immunocompromised pediatric oncology patients all had mild clinical COVID-19 with no directly attributable morbidity and mortality. In four patients, treatment with remdesivir was safe but did not lead to early viral clearance.

Hosted file

COVIDPAEDSONCO_PBC.docx available at <https://authorea.com/users/518156/articles/592424-a-cohort-study-of-covid-19-infection-in-pediatric-oncology-patients-and-the-utility-of-remdesivir-treatment>

Hosted file

COVIDPAEDSONCO_Figures.docx available at <https://authorea.com/users/518156/articles/592424-a-cohort-study-of-covid-19-infection-in-pediatric-oncology-patients-and-the-utility-of-remdesivir-treatment>

Hosted file

COVIDPAEDSONCO_Tables.docx available at <https://authorea.com/users/518156/articles/592424-a-cohort-study-of-covid-19-infection-in-pediatric-oncology-patients-and-the-utility-of-remdesivir-treatment>